Find Nirogacestat manufacturers, exporters & distributors on PharmaCompass

Nirogacestat

Nirogacestat

Synopsis, Chemistry

DEVELOPMENTS

28 Drug(s) in Development

28 Drug(s) in Development

PRICE INFORMATION

API Reference Price, API Imports

DIGITAL CONTENT

25 News

25 News

Product Search

API SUPPLIERS

API Suppliers

US DMFs Filed

CEP/COS Certifications

JDMFs Filed

Other Certificates

Other Suppliers

API REF. PRICE (USD / KG)

506,286

API Market Place

INTERMEDIATES

DOSSIERS // FDF

USA (Orange Book)

Europe

Canada

Australia

South Africa

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

FDF Market Place

EXCIPIENTS

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

Other Listed Suppliers

SERVICES

Also known as: Pf-03084014, 1290543-63-3, Pf-3084014, 865773-15-5, Pf 3084014, Nirogacestat [usan]

Molecular Formula

C₂₇H₄₁F₂N₅O

Molecular Weight

489.6 g/mol

InChI Key

VFCRKLWBYMDAED-REWPJTCUSA-N

FDA UNII

QZ62892OFJ

Nirogacestat is a selective gamma secretase (GS) inhibitor with potential antitumor activity. Nirogacestat binds to GS, blocking proteolytic activation of Notch receptors; Notch signaling pathway inhibition may follow, which may result in the induction of apoptosis in tumor cells that overexpress Notch. The integral membrane protein GS is a multi-subunit protease complex that cleaves single-pass transmembrane proteins, such as Notch receptors, at residues within their transmembrane domains. Overexpression of the Notch signaling pathway has been correlated with increased tumor cell growth and survival.

1 2D Structure

Nirogacestat

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

(2S)-2-[[(2S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]amino]-N-[1-[1-(2,2-dimethylpropylamino)-2-methylpropan-2-yl]imidazol-4-yl]pentanamide

2.1.2 InChI

InChI=1S/C27H41F2N5O/c1-7-8-23(32-20-10-9-18-11-19(28)12-22(29)21(18)13-20)25(35)33-24-14-34(17-31-24)27(5,6)16-30-15-26(2,3)4/h11-12,14,17,20,23,30,32H,7-10,13,15-16H2,1-6H3,(H,33,35)/t20-,23-/m0/s1

2.1.3 InChI Key

VFCRKLWBYMDAED-REWPJTCUSA-N

2.1.4 Canonical SMILES

CCCC(C(=O)NC1=CN(C=N1)C(C)(C)CNCC(C)(C)C)NC2CCC3=C(C2)C(=CC(=C3)F)F

2.1.5 Isomeric SMILES

CCC[C@@H](C(=O)NC1=CN(C=N1)C(C)(C)CNCC(C)(C)C)N[C@H]2CCC3=C(C2)C(=CC(=C3)F)F

2.2 Other Identifiers

2.2.1 UNII

QZ62892OFJ

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 2-(5,7-difluoro-1,2,3,4-tetrahydronaphthalen-3-ylamino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide

2. Pf 03084014

3. Pf 3084014

4. Pf-03084014

5. Pf-3084014

6. Pf03084014

7. Pf3084014

2.3.2 Depositor-Supplied Synonyms

1. Pf-03084014

2. 1290543-63-3

3. Pf-3084014

4. 865773-15-5

5. Pf 3084014

6. Nirogacestat [usan]

7. Pf 03084014

8. Pf3084014

9. Qz62892ofj

10. (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide

11. (2s)-2-[[(2s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]amino]-n-[1-[1-(2,2-dimethylpropylamino)-2-methylpropan-2-yl]imidazol-4-yl]pentanamide

12. Pf-03084014 (pf-3084014)

13. (s)-2-((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-ylamino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide

14. Unii-qz62892ofj

15. Nirogacestat (usan/inn)

16. Nirogacestat [inn]

17. Z-3181

18. Nirogacestat [who-dd]

19. Gtpl7746

20. Chembl1770916

21. Schembl13184754

22. Dtxsid60235679

23. Ex-a855

24. Pf-3084014 (y-secratase)

25. Hms3886p21

26. Bdbm50458159

27. Mfcd19980705

28. Nsc754348

29. S8018

30. Zinc38217837

31. Akos030526383

32. Ccg-269609

33. Cs-1689

34. Db12005

35. Nsc-754348

36. Ncgc00378713-01

37. 2-(5,7-difluoro-1,2,3,4-tetrahydronaphthalen-3-ylamino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide

38. Ac-36191

39. As-56178

40. Hy-15185

41. Pf-03084014-pf-3084014

42. A11993

43. D10960

44. F17429

45. A910640

46. Nirogacestat (pf-03084014, Pf-3084014)

47. Q27088329

48. Pf-03084014;pf-3084014;865773-15-5;

49. (2s)-2-(((2s)-6,8-difluoro-1,2,3,4-tetrahydro-2-naphthalenyl)amino)-n-(1-(2-((2,2-dimethylpropyl)amino)-1,1-dimethylethyl)-1h-imidazol-4-yl)pentanamide

50. (2s)-2-{[(2s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]amino}-n-(1-{1-[(2,2-dimethylpropyl)amino]-2-methylpropan-2-yl}-1h-imidazol-4-yl)pentanamide

51. Pentanamide, 2-(((2s)-6,8-difluoro-1,2,3,4-tetrahydro-2-naphthalenyl)amino)-n-(1-(2-((2,2-dimethylpropyl)amino)-1,1-dimethylethyl)-1h-imidazol-4-yl)-, (2s)-

52. Pentanamide, 2-((6,8-difluoro-1,2,3,4-tetrahydro-2-naphthalenyl)amino)-n-(1-(2-((2,2-dimethylpropyl)amino)-1,1-dimethylethyl)-1h-imidazol-4-yl)-, (2s)-

53. Pentanamide, 2-[(6,8-difluoro-1,2,3,4-tetrahydro-2-naphthalenyl)amino]-n-[1-[2-[(2,2-dimethylpropyl)amino]-1,1-dimethylethyl]-1h-imidazol-4-yl]-, (2s)

2.4 Create Date

2010-07-06

3 Chemical and Physical Properties

Molecular Formula	C₂₇H₄₁F₂N₅O
Molecular Weight	489.6 g/mol
XLogP3	4.8
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	11
Exact Mass	489.32791727 g/mol
Monoisotopic Mass	489.32791727 g/mol
Topological Polar Surface Area	71 Å²
Heavy Atom Count	35
Formal Charge	0
Complexity	685
Isotope Atom Count	0
Defined Atom Stereocenter Count	2
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Pharmacology and Biochemistry

4.1 MeSH Pharmacological Classification

Gamma Secretase Inhibitors and Modulators

Agents that suppress GAMMA-SECRETASE by inhibiting or modulating its activities. Targeted enzymatic activities include its involvement in accumulation of toxic AMYLOID BETA-PEPTIDES (e.g., Aβ42) in ALZHEIMER DISEASE and activation of NOTCH RECEPTOR mediated SIGNAL PATHWAYS in certain cancer types. (See all compounds classified as Gamma Secretase Inhibitors and Modulators.)